Scinai Immunotherapeutics Ltd.
- SCNI
- NASDAQ
- Biotechnology
- Immunotherapeutics
- Infectious/Autoimmune Disease
- Biopharmaceutical R&D
$0.70
Today −6.67%Quote Oct 20, 2026, 02:07 PM UTC
−53.60%over the last month
Max drawdown −63.4%From 1-month high −63.4%3 months −70.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
45
Market value
$9.71B
Quote Oct 20
Floor
$0.40
42.4% below price
Resistance
$1.08
54.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SCNIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free